Analysts tip Inventiva’s lanifibranor as NASH blockbusterInventiva’s lanifibranor has been tipped to become a blockbuster in the fatty liver disease non-alcoholic steatohepatitis (NASH) after it became Share XAnalysts tip Inventiva’s lanifibranor as NASH blockbusterhttps://pharmaphorum.com/news/analyst-tip-inventivas-lanifibranor-as-nash-blockbuster-after-trial-win/